Pfizer TUKYSA gains FDA approval for first-line HER2-positive metastatic breast cancer maintenance
Pfizer’s TUKYSA gained first-line HER2-positive breast cancer maintenance approval after extending median PFS by 8.6 months.
Features & Analysis
Pharma & Biotech
Europe’s HER2 breast cancer standard stood for more than a decade. Enhertu just broke through
The European Commission has approved AstraZeneca and Daiichi Sankyo’s Enhertu with pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed a 44% reduction in the risk of progression or death compared with long-standing THP therapy.
Pharma & Biotech
Why Enhertu’s EU recommendation could end a decade of stability in first-line HER2 breast cancer treatment
EU regulators back Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer, shifting focus to approval, safety and access.
Pharma & Biotech
Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.
Pharma & Biotech
Enhertu plus pertuzumab receives FDA approval for 1st-line HER2-positive metastatic breast cancer: Is the new standard of care here?
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, has received U.S. Food and Drug Administration approval as a first-line treatment for patients with unresectable or metastatic HER2-positive breast cancer, based on results from the DESTINY-Breast09 Phase III trial. The approval marks the first new frontline treatment in over a decade
Pharma & Biotech
Can Pfizer reposition TUKYSA as a first-line maintenance option after HER2CLIMB-05?
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.